ARIAD Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARIAD Pharmaceuticals

ARIA 23.99

0.0%

Feb 17 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: tktom

5/9/2016 12:34:16 PM

of 4474

I expect this is closer to the truth, especially with Denner's comment on the call today:

News for 'ARIA' - (DJ Ariad Pharma Backing Out of Europe -- Market Talk)

12:02 ET - Ariad Pharma's (ARIA) deal to sell its European operators for $140M plus royalties and possible future milestone payments gives the company fresh capital and reduces its operating expenses as the company tries to find profitability, notes RBC. But the bank adds the agreement with Incyte (INCY) "raises the question as to whether potential acquirers of ARIA passed on the whole" firm. The deal also includes INCY getting an exclusive license to make and sell ARIA's Iclusig cancer drug "in Europe and other select countries." ARIA rises 4% after selling off a week ago while INCY--which also released 1Q results this morning, is down 1.7%. ( jonathan.rockoff@wsj.com; @jonathanrockoff)
(END) Dow Jones Newswires
May 09, 2016 12:02 ET (16:02 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.- - 12 02 PM EDT 05-09-16

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next